EBI-005-2

Phase 1Small molecule

EEleven Biotherapeutics

EBI-005-2 is one of 32 small molecule programs targeting Dry Eye Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry Eye SyndromeActive, not recruiting

Dry Eye SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

81 competitors in Dry Eye Syndrome

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

3 2

Alphagan

Cyclosporine a

1 4

Sodium Hyaluronate

Sanofi

Phase 3

1 5

Cosentyx

Ilaris

Restasis

Aurinia Pharmaceuticals

Phase 3

6 8

Cyclosporin a

Novartis

Phase 2

1 9

NOVA22007

SSanten Inc.

Phase 3

1 10

HU007

HHuons Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dry Eye Syndrome1 trial

A Multi-Center Study Subjects With Dry Eye Syndrome

Completed·EEleven Biotherapeutics·Phase 1·NCT01745887·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EBI-005-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EBI-005-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EBI-005-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eleven Biotherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEleven Biotherapeutics

EBI-005-2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dry Eye Syndrome1 trial

References

Drug Info

Quick Facts

Related News